Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Net Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Net Margin for 14 consecutive years, with 12.21% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin fell 1244.0% to 12.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 13.43%, a 485.0% increase, with the full-year FY2025 number at 13.43%, up 485.0% from a year prior.
  • Net Margin was 12.21% for Q4 2025 at Niagen Bioscience, down from 13.47% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 24.65% in Q4 2024 to a low of 51.17% in Q3 2021.
  • A 5-year average of 10.59% and a median of 5.9% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -2158bps in 2021, then soared 3612bps in 2023.
  • Niagen Bioscience's Net Margin stood at 29.98% in 2021, then surged by 77bps to 6.88% in 2022, then surged by 108bps to 0.54% in 2023, then soared by 4483bps to 24.65% in 2024, then crashed by -50bps to 12.21% in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Net Margin are 12.21% (Q4 2025), 13.47% (Q3 2025), and 11.6% (Q2 2025).